Advertisement
Screener

Adicet Bio, Inc. (ACET) Stock-Based Compensation

2.8 / 5 stars · 68/120 Roast Me

Adicet Bio, Inc. Stock-Based Compensation

Adicet Bio, Inc. (ACET) reported Stock-Based Compensation of $1.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Operating Activities

us-gaap:ShareBasedCompensation · last filed 2026-08-05

  • Adicet Bio, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.40M, a 51.72% decline year-over-year.
  • Adicet Bio, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.30M, a 59.03% decline year-over-year.
  • Adicet Bio, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $5.65M, a 49.75% increase year-over-year.
  • Adicet Bio, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $2.50M, a 63.24% decline year-over-year.
  • Adicet Bio, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $14.27M, a 35.83% decline from fiscal 2024.
  • Adicet Bio, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $22.23M, a 9.74% increase from fiscal 2023.
  • Adicet Bio, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $20.26M, a 18.29% increase from fiscal 2022.
  • Adicet Bio, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $17.13M, a 36.89% increase from fiscal 2021.
Period endShare-based Payment Arrangement, Noncash Expense 3 monthShare-based Payment Arrangement, Noncash Expense 3 month as first filedShare-based Payment Arrangement, Noncash Expense 6 monthShare-based Payment Arrangement, Noncash Expense 6 month as first filedShare-based Payment Arrangement, Noncash Expense 9 monthShare-based Payment Arrangement, Noncash Expense 9 month as first filedShare-based Payment Arrangement, Noncash Expense 12 monthShare-based Payment Arrangement, Noncash Expense 12 month as first filed
2026-06-30$1.40M
10-Q · filed 2026-08-05
$2.74M
10-Q · filed 2026-08-05
$8.35M
derived: sum of 3 quarters · filed 2026-08-05
$10.85M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31$1.30M
10-Q · filed 2026-05-13
$6.95M
derived: sum of 2 quarters · filed 2026-05-13
$9.45M
derived: sum of 3 quarters · filed 2026-05-13
$12.35M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31$5.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$8.15M
derived: sum of 2 quarters · filed 2026-03-12
$11.05M
derived: sum of 3 quarters · filed 2026-08-05
$14.27M
10-K · filed 2026-03-12
2025-09-30$2.50M
10-Q · filed 2025-11-05
$5.40M
derived: sum of 2 quarters · filed 2026-08-05
$8.62M
10-Q · filed 2025-11-05
$12.35M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30$2.90M
10-Q · filed 2026-08-05
$6.09M
10-Q · filed 2026-08-05
$9.85M
derived: sum of 3 quarters · filed 2026-08-05
$16.65M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31$3.18M
10-Q · filed 2026-05-13
$6.95M
derived: sum of 2 quarters · filed 2026-05-13
$13.75M
derived: sum of 3 quarters · filed 2026-05-13
$19.75M
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31$3.77M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$10.57M
derived: sum of 2 quarters · filed 2026-03-12
$16.57M
derived: sum of 3 quarters · filed 2026-03-12
$22.23M
10-K · filed 2026-03-12
2024-09-30$6.80M
10-Q · filed 2025-11-05
$12.80M
derived: sum of 2 quarters · filed 2025-11-05
$18.46M
10-Q · filed 2025-11-05
$23.39M
derived: sum of 4 quarters · filed 2025-11-05
2024-06-30$6.00M
10-Q · filed 2025-08-07
$11.68M
10-Q · filed 2025-08-07
$16.59M
derived: sum of 3 quarters · filed 2025-08-07
$22.15M
derived: sum of 4 quarters · filed 2025-08-07
2024-03-31$5.68M
10-Q · filed 2025-05-06
$10.59M
derived: sum of 2 quarters · filed 2025-05-06
$16.15M
derived: sum of 3 quarters · filed 2025-05-06
$21.17M
derived: sum of 4 quarters · filed 2025-05-06
2023-12-31$4.91M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06
$10.47M
derived: sum of 2 quarters · filed 2025-03-06
$15.49M
derived: sum of 3 quarters · filed 2025-03-06
$20.26M
10-K · filed 2025-03-06
2023-09-30$5.56M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06
$10.58M
derived: sum of 2 quarters · filed 2024-11-06
$15.35M
10-Q · filed 2024-11-06
$19.60M
derived: sum of 4 quarters · filed 2024-11-06
2023-06-30$5.02M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13
$9.79M
10-Q · filed 2024-08-13
$14.04M
derived: sum of 3 quarters · filed 2024-08-13
$18.23M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31$4.76M
10-Q · filed 2024-05-14
$9.02M
derived: sum of 2 quarters · filed 2024-05-14
$13.21M
derived: sum of 3 quarters · filed 2024-05-14
$17.54M
derived: sum of 4 quarters · filed 2024-05-14
2022-12-31$4.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19
$8.44M
derived: sum of 2 quarters · filed 2024-03-19
$12.78M
derived: sum of 3 quarters · filed 2024-03-19
$17.13M
10-K · filed 2024-03-19
2022-09-30$4.19M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08
$8.53M
derived: sum of 2 quarters · filed 2023-11-08
$12.88M
10-Q · filed 2023-11-08
$17.16M
derived: sum of 4 quarters · filed 2023-11-08
2022-06-30$4.33M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09
$8.69M
10-Q · filed 2023-08-09
$12.96M
derived: sum of 3 quarters · filed 2023-08-09
$15.49M
derived: sum of 4 quarters · filed 2023-08-09
2022-03-31$4.35M
10-Q · filed 2023-05-09
$8.63M
derived: sum of 2 quarters · filed 2023-05-09
$11.16M
derived: sum of 3 quarters · filed 2023-05-09
$13.82M
derived: sum of 4 quarters · filed 2023-05-09
2021-12-31$4.28M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15
$6.81M
derived: sum of 2 quarters · filed 2023-03-15
$9.47M
derived: sum of 3 quarters · filed 2023-03-15
$12.51M
10-K · filed 2023-03-15
2021-09-30$2.53M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08
$5.19M
derived: sum of 2 quarters · filed 2022-11-08
$8.23M
10-Q · filed 2022-11-08
$9.88M
derived: sum of 4 quarters · filed 2022-11-08
2021-06-30$2.66M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10
$5.70M
10-Q · filed 2022-08-10
$7.35M
derived: sum of 3 quarters · filed 2022-08-10
$10.31M
derived: sum of 4 quarters · filed 2022-08-10
2021-03-31$3.04M
10-Q · filed 2022-05-12
$4.69M
derived: sum of 2 quarters · filed 2022-05-12
$7.66M
derived: sum of 3 quarters · filed 2022-05-12
$8.01M
derived: sum of 4 quarters · filed 2022-05-12
2020-12-31$1.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15
$4.61M
derived: sum of 2 quarters · filed 2022-03-15
$4.96M
derived: sum of 3 quarters · filed 2022-03-15
$5.26M
10-K · filed 2022-03-15
2020-09-30$2.97M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10
$3.32M
derived: sum of 2 quarters · filed 2021-11-10
$3.62M
10-Q · filed 2021-11-10
$3.93M
derived: sum of 4 quarters · filed 2021-11-10
2020-06-30$351.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12
$650.00K
10-Q · filed 2021-08-12
$1.73M
10-Q · filed 2020-07-30
$960.00K
derived: sum of 3 quarters · filed 2021-08-12
$218.00K
derived: sum of 4 quarters · filed 2021-08-12
2020-03-31$299.00K
10-Q · filed 2021-05-17
$975.00K
10-Q · filed 2020-05-07
$609.00K
derived: sum of 2 quarters · filed 2021-05-17
-$133.00K
derived: sum of 3 quarters · filed 2021-05-17
$811.00K
derived: sum of 4 quarters · filed 2021-05-17
2019-12-31$310.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12
-$432.00K
derived: sum of 2 quarters · filed 2021-03-12
$512.00K
derived: sum of 3 quarters · filed 2021-03-12
$1.18M
10-K · filed 2021-03-12
$3.69M
10-K · filed 2020-03-12
2019-09-30-$742.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
$202.00K
derived: sum of 2 quarters · filed 2020-11-05
$865.00K
10-Q · filed 2020-11-05
$2.81M
10-Q · filed 2019-11-05
$1.13M
derived: sum of 4 quarters · filed 2021-03-12
2019-06-30$944.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30
$1.61M
10-Q · filed 2020-07-30
$1.87M
derived: sum of 3 quarters · filed 2021-03-12
$2.50M
derived: sum of 4 quarters · filed 2021-03-12
2019-03-31$663.00K
10-Q · filed 2020-05-07
$930.00K
derived: sum of 2 quarters · filed 2021-03-12
$1.56M
derived: sum of 3 quarters · filed 2021-03-12
$1.96M
derived: sum of 4 quarters · filed 2021-03-12
2018-12-31$267.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12
$896.00K
derived: sum of 2 quarters · filed 2021-03-12
$1.30M
derived: sum of 3 quarters · filed 2021-03-12
$2.48M
10-K · filed 2021-03-12
$2.79M
10-K · filed 2019-03-18
2018-09-30$629.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05
$1.03M
derived: sum of 2 quarters · filed 2019-11-05
$2.21M
10-Q · filed 2019-11-05
$2.38M
derived: sum of 4 quarters · filed 2020-03-12
2018-06-30$402.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14
$1.58M
10-Q · filed 2019-08-14
$1.75M
derived: sum of 3 quarters · filed 2020-03-12
$1.84M
derived: sum of 4 quarters · filed 2020-03-12
2018-03-31$1.18M
10-Q · filed 2019-05-15
$1.35M
derived: sum of 2 quarters · filed 2020-03-12
$1.44M
derived: sum of 3 quarters · filed 2020-03-12
$1.53M
derived: sum of 4 quarters · filed 2020-03-12
2017-12-31$169.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
$260.00K
derived: sum of 2 quarters · filed 2020-03-12
$345.00K
derived: sum of 3 quarters · filed 2020-03-12
$470.00K
10-K · filed 2020-03-12
2017-09-30$91.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13
$176.00K
derived: sum of 2 quarters · filed 2018-11-13
$301.00K
10-Q · filed 2018-11-13
2017-06-30$85.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09
$210.00K
10-Q · filed 2018-08-09
2017-03-31$125.00K
10-Q · filed 2018-05-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
Valion Bio, Inc. (VBIO)United States$0.077B
Lifevantage Corp (LFVN)United States$0.078B15.40
MAIA Biotechnology, Inc. (MAIA)United States$0.077B-2.30
iBio, Inc. (IBIO)United States$0.077B-2.94
Verrica Pharmaceuticals Inc. (VRCA)United States$0.076B-3.39
OS Therapies Inc (OSTX)United States$0.076B-2.17
Gain Therapeutics, Inc. (GANX)United States$0.080B-4.40
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57
Cingulate Inc. (CING)United States$0.073B-2.64
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41